# Sarah Hein

> Sarah Hein is the Houston-based CEO and co-founder of March Biosciences. A Baylor-trained molecular and cellular biologist, she previously co-founded Courier Therapeutics, led research at Resonant Therapeutics, worked as a Mercury Fund venture fellow and served as a founding entrepreneur in residence at TMC Innovation. Her career also includes entrepreneurship workshops, teaching and volunteer work.

- **Role:** CEO and Co-Founder at March Biosciences
- **Organizations:** March Biosciences, Courier Therapeutics, Resonant Therapeutics, Mercury Fund, TMC Innovation, Enventure, Rice University, Baylor College of Medicine, University of Wyoming, Prison Entrepreneurship Program
- **Education:** BS, Molecular Biology with Honors, University of Wyoming, MS, Reproductive Biology, University of Wyoming, PhD, Molecular and Cellular Biology, Baylor College of Medicine
- **Known for:** Co-founded Courier Therapeutics, which was acquired by Valo., Helped launch Enventure’s Foundations workshop series., First Prize with Distinction, 2023 AIM-HI Women’s Venture Competition, awarded to Hein and March from a field of 71 applicants across 15 countries.

## Career timeline

- **2015** — Became an Enventure core member and helped launch the Foundations entrepreneurship workshop series.
- **2016** — Completed her Baylor doctorate, served as a Rice entrepreneurship-course teaching assistant, became a Mercury Fund venture fellow and co-founded Courier Therapeutics as director of development.
- **2016-2019** — Director of Research at Resonant Therapeutics.
- **2019** — Became Vice President of Operations at Courier Therapeutics.
- **2020-2022** — Founding entrepreneur in residence at TMC Innovation’s accelerator.
- **2021** — Her public 2025 CV dates her March Biosciences co-founder and CEO role from March 2021.
- **2023** — Hein and March received First Prize with Distinction at the AIM-HI Women’s Venture Competition.
- **2024** — March announced a $28.4 million Series A on October 23.

## Achievements

- Co-founded Courier Therapeutics, which was acquired by Valo.
- Helped launch Enventure’s Foundations workshop series.
- First Prize with Distinction, 2023 AIM-HI Women’s Venture Competition, awarded to Hein and March from a field of 71 applicants across 15 countries.
- Led March Biosciences when it closed a $28.4 million Series A led by Mission BioCapital and 4BIO Capital in October 2024.

## Latest updates

- **2026-10** — The Texas Life Science Forum’s current speaker profile identifies Hein as March Biosciences’ CEO and co-founder.
- **2026-01** — In PharmaVoice’s 2026 outlook, Hein anticipated more financing events than in 2025 and continued pressure for capital efficiency.
- **2025-04** — TMC Innovation featured Hein’s experience of company building through its entrepreneur in residence program.

## Links

- Website: https://march.bio/
- LinkedIn: https://www.linkedin.com/in/smhein

---

Profile page: https://yespress.io/sarah-hein
Published by YesPress — https://yespress.io
Last updated: 2026-10-25